COMPOSITION active ingredients: 100 ml of solution contain sodium chloride - 0.526 g, potassium chloride - 0.037 g, calcium chloride hexahydrate - 0.055 g, magnesium chloride hexahydrate - 0.030 g, sodium acetate trihydrate - 0.680 g. mmol in 1000 ml of the drug: Sodium ion - 140.0; Potassium ion - 5.0; Calcium ion - 2.5; Magnesium ion - 1.5; Chloride ion - 103.0; Acetate ion - 50.0. DOSAGE FORM Solution for infusion. PHARMACOLOGICAL GROUP Solutions for intravenous administration. Solutions used to correct electrolyte imbalance. ATC code B05B B01. INDICATIONS Hypovolemia and extracellular (isotonic) dehydration due to prolonged vomiting, massive blood loss, diarrhea, extensive burns, severe infectious diseases, shock conditions, the impossibility of oral administration of the required daily intake of water and electrolytes. Used to dissolve other compatible concentrated solutions of drugs for parenteral use. CONTRAINDICATIONS Decompensated heart failure; hyperhydration; hypertensive dehydration; high blood levels of ions that make up the drug (hyperkalemia, hypernatremia, hypercalcemia) oliguria and anuria acute renal failure pulmonary edema, cerebral edema, hypercoagulation, thrombophlebitis; metabolic alkalosis; treatment with large doses of corticosteroids. 

In stock
Guaranteed refund or reship if you haven't received your order
Secure and encrypted payment processing
We ship to over 40 countries including the USA, UK, Europe, Australia and Japan

DOSAGE AND METHOD OF APPLICATION The solution is intended for use only. The dose is prescribed by the doctor. The dose depends on the age, body weight, laboratory parameters, clinical condition of the patient. The usual dose for an adult is 210 ml / h (with a body weight of 70 kg) or 3 ml / kg / hour. The infusion rate for adults is 70 drops / min. The maximum daily dose is 30 ml / kg of body weight and depends on the state of water and electrolyte balance, cardiovascular system and kidney function. The prescription of the solution should be based on the calculated fluid requirements for each individual patient. Parenteral drugs should be visually inspected for particles and discoloration prior to use. ADVERSE REACTIONS Electrolyte metabolism disorders (potassium, calcium, sodium, chlorine), chloride acidosis, overhydration may occur. OVERDOSE Administration of too much solution can lead to imbalance of fluid, electrolytes (hypervolemia, hypernatremia, hypercalcemia, hyperchloremia) and acid-base balance. Treatment. In these conditions, it is necessary to stop the administration of the drug. In case of symptoms of overhydration, prescribe diuretics or laxatives, in case of hypervolemia, use the method of extrarenal cleansing, with a combination of extracellular hyperhydration with intracellular dehydration, and also with hypernatremia, inject a 5% glucose solution. APPLICATION DURING PREGNANCY OR BREASTFEEDING Studies on the use of the drug in pregnant women have not been conducted. It is not known whether this drug is excreted in breast milk. Since most drugs are excreted in breast milk, the drug should be administered with caution during lactation. CHILDREN Do not use for children. FEATURES OF APPLICATION During long-term parenteral therapy, it is necessary to determine laboratory parameters and give a clinical assessment of the patient's condition to monitor the concentration of electrolytes and water-electrolyte balance every 6:00 (depending on the rate of infusion). Intravenous fluids can cause fluid and / or fluid overload, overhydration, congestion, and pulmonary edema. The risk of developing dilution is inversely proportional to the concentration of electrolytes. The risk of developing solution overload, causing congestion with peripheral edema and pulmonary edema, is directly proportional to the concentration of electrolytes. Due to the content of sodium ions, the solution should be used with caution in patients with renal and cardiovascular insufficiency, congestive heart failure, especially in the postoperative period or in elderly patients, as well as in patients with clinical conditions accompanied by sodium retention and edema. Solutions containing sodium should be used with caution in patients receiving corticosteroids or corticotropin. The potassium content requires caution when using the solution to patients with heart disease, hyperkalemia, severe renal failure and clinical conditions accompanied by potassium retention in the body. Calcium administration should be done under ECG monitoring, especially in patients receiving digitalis medications. Serum calcium levels do not always reflect tissue calcium levels. In patients with reduced renal excretory function, administration of the solution can lead to sodium or potassium retention. The presence of calcium ions requires caution when administered simultaneously with blood preparations due to the likelihood of coagulation development. Prescribing parenteral calcium should be given special attention to patients receiving cardiac glycosides. This solution is intended for intravenous use using sterile equipment. It is recommended that the intravenous system be changed at least every 24 hours. The solution should be used only when it is transparent and the bottle is sealed. The doctor should also take into account the possibility of developing adverse reactions to drugs used simultaneously with Izosol. If an adverse reaction occurs, you need to stop the infusion, assess the patient's condition and prescribe the necessary therapeutic measures. ABILITY TO INFLUENCE THE RATE OF RESPONSE WHEN DRIVING MOTOR VEHICLES OR OTHER MECHANISMS During treatment, care must be taken when driving and operating mechanisms. INTERACTION WITH OTHER DRUGS AND OTHER KINDS OF INTERACTIONS It is possible to increase sodium retention in the body with the simultaneous use of such drugs: non-steroidal anti-inflammatory drugs, androgens, anabolic hormones, estrogens, corticotropin, mineralocorticosteroids, or corticosteroids. When used with potassium-sparing diuretics, ACE inhibitors and potassium preparations, the risk of hyperkalemia increases. In combination with cardiac glycosides, the likelihood of their toxic effects increases.

Tags: Izosol